. Afssaps, Anticoagulants directs oraux: fiche de transparence et texte utilisé pour la rédaction des AMM

A. K. Afssaps, fiche de transparence et texte utilisé pour la rédaction des AMM, 2011.

R. Bauersachs, B. S. Brenner, B. Buller, H. Decousus, and H. , Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, issue.26, pp.3632499-510, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00724645

H. Buller, Once daily oral rivaroxaban versus placebo in the long term prevention of recurrent symptomatic venous thromboembolism. The Einstein-Extension study, Blood, 2009.

S. Connolly, E. J. Joyner, and C. , Apixaban in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.364, issue.9, pp.806-817, 2011.
DOI : 10.1056/NEJMoa1007432

S. Connoly, E. M. Yusuf, S. Eikelboom, J. Oldgren, J. Parekh et al., Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-1151, 2009.
DOI : 10.1056/NEJMoa0905561

C. S. Miller, S. M. Ba, . Grandi, A. Msc, M. Shimony et al., Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation, The American Journal of Cardiology, vol.110, issue.3, pp.110453-460, 2012.
DOI : 10.1016/j.amjcard.2012.03.049

J. Douxfils, M. F. Robert, S. Chatelain, C. Chatelain, B. Dogne et al., Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate, Thromb Haemost, issue.5, pp.2012-107985

!. Dd-!-9, J. Eikelboom, O. Donnell, M. Yusuf, S. Diaz et al., Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment, Am Heart J, issue.3, pp.159348-353, 2010.

M. Ezekowitz, C. S. Parekh, and A. , Randomized evaluation of long term anticoagulant therapy, warfarin compared with dabigatran, Am Heart J, vol.361, pp.1139-1151, 2009.

M. Ezekowitz, R. P. Nehmiz, G. Simmers, T. Nagarakanti, R. Parcham-azad et al., Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvanvular atrial fibrillation The American Journal of cardiology, pp.1001419-1426, 2007.

M. Gnoth, B. U. Muenster, U. Schwartz, T. Sandmann, and S. , In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban, Journal of Pharmacology and Experimental Therapeutics, vol.338, issue.1, pp.372-80, 2011.
DOI : 10.1124/jpet.111.180240

C. Granger, A. J. Mcmurray, J. Lopes, R. Hylek, E. Hanna et al., Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.11, pp.981-992, 2011.
DOI : 10.1056/NEJMoa1107039

S. Hartter, K. M. Sharma, A. Nehmiz, G. Lemke, U. Timmer et al., Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin, British Journal of Clinical Pharmacology, vol.86, issue.2
DOI : 10.1111/j.1365-2125.2012.04218.x

P. Kirchhof and . Ehra, Practical guide on the use of new oral anticoagulants in patients with non valvular atrial fibrillation: executive summary, European Heart Journal, vol.15, pp.625-651, 2013.

M. O. Kate, . Dell, . Pharmd, J. Igawa, and . Hsin, New oral anticoagulants for atrial fibrillation: A review of clinical trials( 30)%+*3, 10#( )*'#(4&$1"(51*$%6-"(+&-1#( +%'6()"1'%81"#(51"#+1%5$%&'#()9*'$%+&*,-.*'$, pp.75-76

Q. $-09774a and %. !. , 938! a.9;:.4,7%8b! A$09774a,%! 8I0-39043,<:%! ,#3749@:.4,7%b! ,#37f@74#,%##%b! ,#37474@A,1,%##%! 9:! ,#3740:8@:.4,(30)%+*3, 7%!9:!-$7,@471,<:%W! ! 210"#()*'#( 4&$1"( "D"1+%+"( 5&-1( +"#( 30)%+*3#( +%'6( )"1'%81"#( 51"#+1%5$%&'#( )9*'$%+&*, pp.7-8

!. , !. Odgel, !. , !. Ldgdl, and !. '. , ($1*'+I"()9J,"(*55*1$

K. , !. 4#3, >. , !. #a, !. #a et al., #3,@94a:.43,9#!974, pp.78-79